LEXXW - Lexaria Appoints New Chief Financial Officer
(TheNewswire)
Kelowna, British Columbia – TheNewswire - June 12, 2023 –Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the“Company” or “Lexaria”), a global innovator in drug deliveryplatforms announces the appointment of a new Chief Financial Officer.
Effective immediately, Mike Shankman has been appointedas outsourced CFO. Mike is an experienced accounting and financeprofessional who has held senior positions with companies in thebiotechnology, medical devices, and software as a service industries.In his role as a consultant with NOW CFO, one of his current clientsis a publicly traded clinical-stage biopharmaceutical company. Formerclients include a medical device maker for which Mike collaboratedwith independent auditors and investment bankers through thecompletion of an initial public offering. The client began trading onthe NASDAQ in 2022.
Mike holds an active license as a Certified PublicAccountant and a Masters in Business Administration with a Financeconcentration from California State University, East Bay. He liveswith his wife in Danville, California. Mr. Chris Bunka will alsoassume the role of principal financial officer at this time.
Lexaria is grateful to its outgoing CFO, Mr. GregDowney, for his many contributions and wishes him every success in hisfuture endeavours.
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.’s patented drug deliverytechnology, DehydraTECH™, improves the way active pharmaceuticalingredients (APIs) enter the bloodstream through oral delivery. Since2016, DehydraTECH has repeatedly demonstrated the ability to increasebio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors andmore. DehydraTECH has also evidenced an ability to deliver some drugsmore effectively across the blood brain barrier. Lexaria operates alicensed in-house research laboratory and holds a robust intellectualproperty portfolio with 30 patents granted and many patents pendingworldwide. For more information, please visit www.lexariabioscience.com .
CAUTION REGARDING FORWARD-LOOKINGSTATEMENTS
This press release includes forward-looking statements.Statements as such term is defined under applicable securities laws.These statements may be identified by words such as"anticipate," "if," "believe,""plan," "estimate," "expect,""intend," "may," "could,""should," "will," and other similar expressions.Such forward-looking statements in this press release include, but arenot limited to, statements by the company relating the Company’sability to carry out research initiatives, receive regulatoryapprovals or grants or experience positive effects or results from anyresearch or study. Such forward-looking statements are estimatesreflecting the Company's best judgment based upon current informationand involve a number of risks and uncertainties, and there can be noassurance that the Company will actually achieve the plans,intentions, or expectations disclosed in these forward-lookingstatements. As such, you should not place undue reliance on theseforward-looking statements. Factors which could cause actual resultsto differ materially from those estimated by the Company include, butare not limited to, government regulation and regulatory approvals,managing and maintaining growth, the effect of adverse publicity,litigation, competition, scientific discovery, the patent applicationand approval process, potential adverse effects arising from thetesting or use of products utilizing the DehydraTECH technology, theCompany’s ability to maintain existing collaborations and realizethe benefits thereof, delays or cancellations of planned R&D thatcould occur related to pandemics or for other reasons, and otherfactors which may be identified from time to time in the Company'spublic announcements and periodic filings withthe US Securities and Exchange Commission on EDGAR. The Companyprovides links to third-party websites only as a courtesy to readersand disclaims any responsibility for the thoroughness, accuracy ortimeliness of information at third-party websites. There is noassurance that any of Lexaria’s postulated uses, benefits, oradvantages for the patented and patent-pending technology will in factbe realized in any manner or in any part. No statement herein has beenevaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat,cure or prevent any disease. Any forward-looking statements containedin this release speak only as of the date hereof, and the Companyexpressly disclaims any obligation to update any forward-lookingstatements or links to third-party websites contained herein, whetheras a result of any new information, future events, changedcircumstances or otherwise, except as otherwise required bylaw.
INVESTOR CONTACT:
George Jurcic - Head of InvestorRelations
Copyright (c) 2023 TheNewswire - All rights reserved.